Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Not yet recruiting · NCT06254066 · Registry updated 2024-02-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer | Female Breast Cancer Patients; HRD Positive Advanced Breast Cancer; Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | Not yet recruiting | Phase 2 | 2024-02-12 | NCT06254066 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jiangsu Hengrui Pharmaceutical Co., Ltd. | 29 |
| Zhejiang Cancer Hospital | 142 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||